TABLE 2.
Effect of LT-IIa on ricin-specific GMT and TNA when combined with RiVax or RVEc
| RiVax (2 or 3×)a |
||||||
|---|---|---|---|---|---|---|
| LT-IIa (μg) | RVEc (2×) on day 17a |
Day 17 |
Day 27 |
|||
| GMT | % Viabb | GMT | % Viabb | GMT | % Viabb | |
| 1 | 18,102 | 1 | 33,779 | 4 | 72,408 | 90 |
| 0.3 | 18,102 | 1 | 15,759 | 2 | 41,587 | 65 |
| 0.1 | 11,404 | 0 | 5,198 | 1 | 31,517 | 59 |
| 0.03 | 11,404 | 2 | 7,352 | 2 | 54,875 | 54 |
| 0 | 1,008 | 0 | 159 | 1 | 16,890 | 9 |
a
Antigen and number of immunizations. Both antigens were administered at 5 μg.
b
Mean Vero cell viability with sera diluted 1:50, as described in Materials and Methods.